Rosen Law Firm announced on April 25 that it is investigating potential securities claims for shareholders of ADMA Biologics, Inc. following allegations that the company may have issued misleading business information to investors.
The announcement comes after a sharp drop in ADMA Biologics’ stock price, which fell by 16.6% on March 24, following the release of a report by short seller Culper Research. The report alleged that the company engaged in channel stuffing to inflate its revenue growth, as reported by Investing.com.
According to Rosen Law Firm, investors who purchased securities of ADMA Biologics may be entitled to compensation without out-of-pocket fees or costs through a contingency fee arrangement. The firm is preparing a class action seeking recovery of investor losses and encourages affected shareholders to contact them for more information about joining the prospective class action.
Rosen Law Firm highlighted its experience in securities class actions and shareholder derivative litigation. The firm said it has achieved significant settlements for investors and has been recognized for its leadership in this area. In particular, Rosen Law Firm noted it secured the largest ever securities class action settlement against a Chinese company at the time and was ranked No. 1 by ISS Securities Class Action Services for number of settlements in 2017.
PR Newswire operates globally across more than 170 countries and supports press release distribution in over 40 languages, according to the official website. It collaborates with over 500,000 media outlets and influencers worldwide through its network of newsrooms and expert editors with more than ten years’ experience providing support around-the-clock and SEO guidance. PR Newswire also offers services such as AI-enhanced content tools and social sharing features as outlined on their official website.
The broader implications of this investigation could impact investor confidence not only in ADMA Biologics but also among other companies facing similar allegations from short sellers or regulatory scrutiny.
